Compare Dyne Therapeutics Inc. Common Stock (DYN) vs NetEase Inc (NTES) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs NetEase Inc — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.08 (market cap $2.86B), while NetEase Inc trades at $125.34 (market cap $79.76B). The key difference: NetEase Inc is far larger — about 27.9× Dyne Therapeutics Inc. Common Stock's market cap, and NetEase Inc pays a 2.35% dividend while Dyne Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and NetEase Inc for 73 Days on average.
| DYN | NTES | |
|---|---|---|
Market Cap | $2.86B | $79.76B |
Volume | 3,341,579 | 503,697 |
Sector | Health | Technology |
52-Week High | $26.78 | $152.85 |
52-Week Low | $14.60 | $109.26 |
Typical Hold Time | 0 Days | 73 Days |
Enterprise Value | $2.18B | $55.44B |
Dividend Yield | — | 2.35% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
NTES trades at $123.73, down 1.34% on the day, with a bullish technical signal from moving averages and oscillators. The company reported Q2 2026 revenue of $4.4 billion, an 8% year-over-year increase, though EPS missed expectations. Strong fundamentals include a 27.88% net income margin and robust cash flow from operations of $50.74 billion in 2025. Recent news highlights global expansion and AI investments as key growth drivers.
The outlook remains positive with an 81.82% analyst buy rating and a consensus price target of $168.00, implying significant upside. Key risks include earnings volatility, competitive pressures in gaming, and macroeconomic sensitivity. The stock's current valuation at a P/E of 16.58 offers a reasonable entry point for long-term growth investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About NetEase Inc
NetEase, which started on an internet portal service in 1997, is a leading online services provider in China. Its key services include online/mobile games, cloud music, media, advertising, email, live streaming, online education, and e-commerce. The company develops and operates some of the China's most popular PC client and mobile games, and it partners with global leading game developers, such as Blizzard Entertainment and Mojang (a Microsoft subsidiary).
Read more on NTES →
